The report “Metastatic Pancreatic Cancer – Pipeline Review, H1 2016” provides comprehensive information on the therapeutics under development for Metastatic Pancreatic Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Pancreatic Cancer and features dormant and discontinued projects.
Complete Report Details Available at https://www.wiseguyreports.com/reports/metastatic-pancreatic-cancer-pipeline-review-h1-2016 .
The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Inquire more about this report at https://www.wiseguyreports.com/enquiry/metastatic-pancreatic-cancer-pipeline-review-h1-2016 .
Metastatic Pancreatic Cancer – Companies Involved in Therapeutics Development:
Aduro BioTech, Inc.
Array BioPharma Inc.
Axcentua Pharmaceuticals AB
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Clovis Oncology, Inc.
Cornerstone Pharmaceuticals, Inc.
CTI BioPharma Corp.
Eleison Pharmaceuticals LLC
Eli Lilly and Company
Ensol Biosciences Inc.
Erytech Pharma SA
F. Hoffmann-La Roche Ltd.
Fountain Biopharma Inc.
Gilead Sciences, Inc.
HanAll Biopharma Co., Ltd.
Immodulon Therapeutics Ltd.
MabVax Therapeutics Holdings, Inc.
Merck & Co., Inc.
Merrimack Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc.
NanoCarrier Co., Ltd.
Natco Pharma Limited
NewLink Genetics Corporation
Oncolytics Biotech Inc.
Oryx GmbH & Co. KG
Pharma Mar, S.A.
Phoenix Biotechnology, Inc.
Precision Biologics, Inc.
Redx Pharma Plc
Rexahn Pharmaceuticals, Inc.
Silence Therapeutics Plc
Zeria Pharmaceutical Co., Ltd.
– The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer
– The report reviews pipeline therapeutics for Metastatic Pancreatic Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Metastatic Pancreatic Cancer therapeutics and enlists all their major and minor projects
– The report assesses Metastatic Pancreatic Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Metastatic Pancreatic Cancer
Reasons to buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
P: +44 208 133 9349
M: +1 646 845 9349